# Afatinib on CNS Metastases and LMD in EGFR Mutation Positive NSCLC

> **NCT03711422** · PHASE1 · TERMINATED · sponsor: **National Cancer Centre, Singapore** · enrollment: 2 (actual)

## Conditions studied

- Non-small Cell Lung Cancer
- Leptomeningeal Disease
- Central Nervous System Metastases

## Interventions

- **DRUG:** Afatinib
- **DRUG:** Afatinib

## Key facts

- **NCT ID:** NCT03711422
- **Lead sponsor:** National Cancer Centre, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-11-16
- **Primary completion:** 2019-12-20
- **Final completion:** 2019-12-20
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Decision to close the trial made due to low recruitment.
- **Last updated:** 2022-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03711422

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03711422, "Afatinib on CNS Metastases and LMD in EGFR Mutation Positive NSCLC". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03711422. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*